RESUMEN
Objective To isolate and identify anti-tumor constituents from Lysimachia christinae Hance.Methods The compounds were isolated and purified by chromategraphy on AB-8 macroporous resin, silica gel, Sephadex LH-20, ODS and preparative HPLC.Their structures were elucidated using chemical and spectroscopic methods.All thecompounds obtained were evaluated on their growth inhibitory effects in vitro using the MTT method.Results Eleven compounds were isolated from the whole plant of L.christinae Hance and were identified as 3,3'-dimethoxy-6,6'-di[(Z)-pentadec-10-en-1-yl]-[1,1'-bi(cyclohexane)]-3,3',6,6'-tetraene-2,2',5,5'-tetraone(1),physcion(2),munjistin(3), 9,16-dioxooctadec-10,12,14-trienoic acid(4),cyclamiretinA-3-O-{β-D-xylopyranosyl-(1→2)-β-D-glucopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→4)]-α-L-arabinopyranoside(5),lysikoianoside(6),quercetin-3-O-glucopyranoside(7),isorhamnetin3-O-β-D-galactopyranoside(8),3',4',5',5,7-pentahydroxyflavone(9), rutin(10), and quercetin(11).The screening results of antitumor activity in vitro showed that IC50 of compound 5 for human cervical carcinoma cells HeLa, human osteosarcoma cells U20S, human lung adenocarcinoma cells PC-9,and human colorectal carcinoma cells CT-26 was 2.29, 1.22, 1.43, and 1.29 μmol/L respectively.Conclusion Compound 1 is a new compound and compounds 2-4 are isolated from the plants of Lysimachia for the first time.Compound 5 shows obvious inhibitory effects on tumor cell growth in vitro.
RESUMEN
Objective: The differences in the compounds between Lysimachia christinae and Desmodium styracifolium were compared in order to provide the references for pharmacodynamic differences of them. Methods: The RP-HPLC-UV and RP-HPLC-ELSD fingerprints of L. christinae and D. styracifolium were established, and the common peaks of two kinds of fingerprints were compared. Results: The HPLC-UV fingerprints of L. christinae were obviously different from the HPLC-ELSD fingerprints, and the strong peaks detected in UV were not the same as what detected in ELSD, so were those of D. styracifolium. There were 14 and 5 common peaks, respectively in the HPLC-UV and HPLC-ELSD fingerprints of L. christinae, while 28 and 18 common peaks, respectively in the HPLC-UV and HPLC-ELSD fingerprints of D. styracifolium. The similarities of chromatograms of D. styracifolium were better than those of L. christinae. Four common peaks were identified in the HPLC-UV fingerprints of L. christinae and D. styracifolium, and two common peaks in their HPLC-ELSD fingerprints. Conclusion: It is better using HPLC-ESLD to establish the fingerprints of L. christinae and D. styracifolium. The chemical constituents of L. christinae were significantly different between the different batches. However, little variation was found in the chromatograms between the different batches of D. styracifolium. The two plants may contain two same compounds with high content, which may have the function as the substantial bases of their treatments for the same indication. However, they may have their special efficacies.
RESUMEN
OBJECTIVE: To analyze the genetic diversity of Lysimachia christinae Hance germplasm resources from 36 different places of origin with ISSR DNA markers. METHODS: Ten primers screened from 45 ISSR primers wrea mplified with PCR and the amplification products were examined by 1.5% agarose gel electrophoresis. POPGENE32 software was used for statistical analysis of genetic parameters and UPGMA method (NTSYS2.10 software) for cluster analysis and dendrogram constructing. RESULTS: A total of 91 sites were amplified from the 10 ISSR primers, of which 80 sites were polymorphic loci. The percentage of total polymorphic loci (PBB) was 87.91%. The number of observed alleles (Na) was 1.879 1 and the number of effective alleles was number (Ne) 1.381 7. The Nei's genetic diversity index (He) was 0.239 0 and the Shannon information index (I) was 0.374 5. The genetic similarity coefficient of the 36 germplasm resources varied from 0.69 to 0.97 and the 36 materials couldbe divided into six categories at the similarity coefficient of 0.76. Clustering results showed that the samples within small geographic range clustered together in the dendrogram, indicating the nearer genetic relationships of them. Meanwhile, the samples from different provinces or cities could not be differentiated from each other through cluster analysis. CONCLUSION: The germplasm resources of Lysimachia christinae have rich genetic diversities. The genetic diversities of Lysimachia christinae have no significant correlation with their geographic distribution.
RESUMEN
OBJECTIVE: To investigate the hepatoprotective effects of Lysimachia christinae Hance against acute liver injury induced by tripterygium glycosides (TG) in vivo and the related mechanism for the first time. METHODS: The mice were administered ethanol extract of L. christinae (JE), water extract of L. christinae (JW), and bifendate by ig for seven consecutive days. 12 h after the last dose, the mice were orally given TG 270 mg · kg-1 except those in the normal group. Serum and liver tissue samples were collected at 18 h after TG treatment. Besides, the amounts of quercetin and kaempferol in JE and JW were analyzed by high-performance liquid chromatography (HPLC). RESULTS: TG-induced elevated serum alanine transferase(ALT) and aspartate transaminase (AST) activities were significantly reduced by JE(100, 200 mg · kg-1) in dose-dependent manners, but not by JW. Further analysis demonstrated that lipid peroxidation(LPO) level significantly decreased, while superoxide dismutase(SOD) and catalase(CAT) activities increased in livers of JE-treated mice. Besides, the amounts of quercetin and kaempferol were 9.8 and 8.9 mg · g-1 in JE, and 2.8 and 1.9 mg · g-1 in JW, respectively. CONCLUSION: This study for the first time demonstrates that L. christinae can protect against TG-induced acute liver injury in dose-dependent manners in vivo, the potential mechanism may be related to inhibiting liver oxidative stress injury, and the hepatoprotective activity may be correlated with the contents of quercetin and kaempferol. Copyright 2013 by the Chinese Pharmaceutical Association.